

Neoadjuvant Chemotherapy and Bevacizumab for HER2

New England Journal of Medicine

366, 299-309

DOI: [10.1056/nejmoa1111065](https://doi.org/10.1056/nejmoa1111065)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Primary intracranial myxopapillary ependymomas: report of two cases and review of the literature. <i>Acta Radiologica</i> , 2004, 45, 344-347.	0.5	25
2	Lessons from the neoadjuvant setting on how best to choose adjuvant therapies. <i>Breast</i> , 2011, 20, S142-S145.	0.9	20
3	Targeting Angiogenesis in Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, 1014-1026.	1.9	22
5	Targeting triple-negative breast cancer: optimising therapeutic outcomes. <i>Annals of Oncology</i> , 2012, 23, 2223-2234.	0.6	141
7	Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, e13-e17.	1.9	7
8	Triple-negative breast cancer: are we making headway at least?. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 195-210.	1.4	75
9	Angiogenesis as a therapeutic target in breast cancer. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012, 12, 1230-1238.	1.1	9
10	Neoadjuvant bevacizumab treatment—signal or noise?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 191-192.	12.5	0
11	Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 453-463.	0.6	21
12	Bevacizumab and breast cancer: what does the future hold?. <i>Future Oncology</i> , 2012, 8, 403-414.	1.1	36
13	Bevacizumab in Neoadjuvant Treatment for Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 1637-1640.	13.9	7
14	Fighting Fire with Fire: Rekindling the Bevacizumab Debate. <i>New England Journal of Medicine</i> , 2012, 366, 374-375.	13.9	31
15	Breast Cancer 2012 - New Aspects. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 602-615.	0.8	19
16	Advances in Breast Cancer — Looking Back over the Year. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 1117-1129.	0.8	17
17	Adjuvant chemotherapy after D2 gastrectomy for gastric cancer. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 192-194.	12.5	16
18	Sorafenib in locally advanced or metastatic breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1177-1191.	1.9	21
19	Inhibiting Angiogenesis in Breast Cancer: The Beginning of the End or the End of the Beginning?. <i>Journal of Clinical Oncology</i> , 2012, 30, 898-901.	0.8	29
21	Targeted therapies in breast cancer. <i>Swiss Medical Weekly</i> , 2012, 142, w13550.	0.8	9

#	ARTICLE	IF	CITATIONS
22	The role of targeted therapy and biomarkers in breast cancer treatment. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 807-819.	1.7	36
23	EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 753-761.	2.7	148
24	Link between endometriosis and ovarian-cancer subtypes. <i>Lancet Oncology</i> , The, 2012, 13, 326-328.	5.1	6
25	Inflammatory HER2-positive breast cancer. <i>Lancet Oncology</i> , The, 2012, 13, 324-326.	5.1	1
26	The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. <i>Breast Cancer Research</i> , 2012, 14, R145.	2.2	34
27	Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours. <i>British Journal of Surgery</i> , 2012, 100, 5-14.	0.1	5
28	Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012, 17, 229-239.	1.0	34
29	Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. <i>Breast Diseases</i> , 2012, 23, 351-352.	0.0	0
30	Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 593-602.	1.5	87
32	Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology. <i>BMC Women's Health</i> , 2012, 12, 35.	0.8	25
33	First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study. <i>Oncology</i> , 2012, 82, 218-227.	0.9	47
34	Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 310-320.	13.9	416
35	Evaluation of changes in breast architecture after preoperative chemotherapy for breast cancer. <i>American Journal of Surgery</i> , 2012, 204, 902-909.	0.9	0
36	Potential practice-changing therapies in breast cancer: The year in review. <i>Community Oncology</i> , 2012, 9, S40-S43.	0.2	0
37	Breast cancer molecular subtypes – Modern therapeutic concepts for targeted therapy of a heterogeneous entity. <i>Maturitas</i> , 2012, 73, 288-294.	1.0	20
38	Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts. <i>Molecular Oncology</i> , 2012, 6, 418-427.	2.1	19
40	Neoadjuvant Therapy for Triple-Negative Breast Cancer: The Challenge of Translating Biological Concepts into Effective Treatments. <i>Current Breast Cancer Reports</i> , 2012, 4, 240-248.	0.5	0
41	Novel targeted agents for the treatment of advanced breast cancer. <i>Future Medicinal Chemistry</i> , 2012, 4, 893-914.	1.1	10

#	ARTICLE	IF	CITATIONS
42	Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. <i>Journal of Oncology</i> , 2012, 2012, 1-8.	0.6	79
43	Lessons Learned from the Bevacizumab Experience. <i>Cancer Control</i> , 2012, 19, 309-316.	0.7	23
44	Targeted therapy for triple-negative breast cancer: Where are we?. <i>International Journal of Cancer</i> , 2012, 131, 2471-2477.	2.3	76
46	Neoadjuvant Clinical Trials for the Treatment of Primary Breast Cancer: The Experience of the German Study Groups. <i>Current Oncology Reports</i> , 2012, 14, 27-34.	1.8	4
47	Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. <i>Radiation Oncology</i> , 2013, 8, 90.	1.2	36
48	Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies. <i>Drugs</i> , 2013, 73, 1257-1265.	4.9	40
49	The Future of Chemotherapy in the Era of Personalized Medicine. <i>Current Breast Cancer Reports</i> , 2013, 5, 57-68.	0.5	2
50	Circulating tumor cells in breast cancer. <i>Clinica Chimica Acta</i> , 2013, 423, 39-45.	0.5	22
51	The Management of Early-Stage and Metastatic Triple-Negative Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 737-749.	0.9	80
52	Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1485-1491.	1.1	10
53	The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?. <i>SpringerPlus</i> , 2013, 2, 202.	1.2	3
54	Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 933-942.	5.1	370
55	State of the art in neoadjuvant therapy of breast cancer. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 284-285.	2.2	2
56	Triple-Negative Breast Cancer and the Need for New Therapeutic Targets. <i>American Journal of Pathology</i> , 2013, 183, 1064-1074.	1.9	135
57	Selecting the neoadjuvant treatment by molecular subtype: How to maximize the benefit?. <i>Breast</i> , 2013, 22, S149-S151.	0.9	24
58	Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBC 44). <i>Annals of Oncology</i> , 2013, 24, 2978-2984.	0.6	121
59	Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 3102-3110.	1.3	32
60	A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 331-339.	1.1	22

#	ARTICLE	IF	CITATIONS
62	Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades. Archives of Gynecology and Obstetrics, 2013, 288, 1203-1212.	0.8	9
63	Contrasting Hypoxic Effects on Breast Cancer Stem Cell Hierarchy Is Dependent on ER- α Status. Cancer Research, 2013, 73, 1420-1433.	0.4	56
64	Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients. Archives of Gynecology and Obstetrics, 2013, 287, 337-344.	0.8	13
65	Targeted Therapy for Breast Cancer. American Journal of Pathology, 2013, 183, 1096-1112.	1.9	100
66	Phase 1 Clinical Trial of Stereotactic Body Radiation Therapy Concomitant With Neoadjuvant Chemotherapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1193-1199.	0.4	69
67	Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. Breast, 2013, 22, 470-475.	0.9	13
68	Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer. Breast Diseases, 2013, 24, 66-68.	0.0	1
69	New Developments and Future Directions in Systemic Therapy. Clinical Oncology, 2013, 25, 117-126.	0.6	11
70	Adjuvant bevacizumab: positive data from a negative trial. Lancet Oncology, The, 2013, 14, 910-911.	5.1	2
71	Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response. Clinical and Translational Oncology, 2013, 15, 810-817.	1.2	11
72	Therapeutic targets in triple negative breast cancer. Journal of Clinical Pathology, 2013, 66, 530-542.	1.0	117
73	Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts. Molecular Oncology, 2013, 7, 130-142.	2.1	26
74	Current approaches for neoadjuvant chemotherapy in breast cancer. European Journal of Pharmacology, 2013, 717, 58-66.	1.7	19
75	Novel strategies towards the use of anti-angiogenic agents in breast cancer. European Journal of Pharmacology, 2013, 717, 36-39.	1.7	5
76	Emerging therapies for triple-negative breast cancer. Breast Cancer Management, 2013, 2, 47-55.	0.2	1
77	Molecular mapping the presence of druggable targets in preinvasive and precursor breast lesions: A comprehensive review of biomarkers related to therapeutic interventions. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1835, 230-242.	3.3	6
78	Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) \pm bevacizumab â€œ Results of the randomised GeparQuinto study (GBG 44). European Journal of Cancer, 2013, 49, 2284-2293.	1.3	75
79	Molecular imaging for monitoring treatment response in breast cancer patients. European Journal of Pharmacology, 2013, 717, 2-11.	1.7	14

#	ARTICLE	IF	CITATIONS
80	The evolving landscape of protein kinases in breast cancer: Clinical implications. <i>Cancer Treatment Reviews</i> , 2013, 39, 68-76.	3.4	20
81	Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6360-6370.	3.2	82
82	Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. <i>Annals of Oncology</i> , 2013, 24, 702-709.	0.6	64
83	Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 255-259.	1.1	13
84	Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions. <i>Current Molecular Medicine</i> , 2013, 13, 165-178.	0.6	13
85	Primary Therapy in Breast Cancer: What Have We Learned from Landmark Trials?. <i>Women's Health</i> , 2013, 9, 583-593.	0.7	0
88	Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. <i>Annals of Oncology</i> , 2013, 24, 1491-1498.	0.6	74
89	Multicentre phase II trial of bevacizumab combined with docetaxel+carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). <i>Annals of Oncology</i> , 2013, 24, 1485-1490.	0.6	31
90	RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2013, 24, 632-639.	0.6	22
91	Update on neoadjuvant/preoperative therapy of breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2013, 25, 66-73.	0.9	19
92	Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake. <i>Cancer Research</i> , 2013, 73, 3347-3355.	0.4	103
94	Chemotherapy-related cardiotoxicity. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2013, 7, 87-98.	1.0	6
95	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e22789.	2.1	92
96	Triple-negative breast cancer: molecular characterization and targeted therapies. <i>Breast Cancer Management</i> , 2013, 2, 417-430.	0.2	1
98	Antiangiogenic treatment approaches in breast cancer. <i>Breast Cancer Management</i> , 2013, 2, 397-406.	0.2	0
99	Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 3190-3200.	3.9	527
100	A Case of Aggressive Primary Squamous Cell Carcinoma of the Breast with the Overexpression of Epidermal Growth Factor Receptor. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of)</i> Tj ETQq0 0 0 rg80/Overlock 10 Tf 5		
101	Radiation Oncologists' View on the Zurich Consensus. <i>Breast Care</i> , 2013, 8, 448-452.	0.8	2

#	ARTICLE	IF	CITATIONS
102	Expression of VEGF and Semaphorin Genes Define Subgroups of Triple Negative Breast Cancer. PLoS ONE, 2013, 8, e61788.	1.1	60
103	Neoadjuvant Chemotherapy for Breast Cancer. , 0, , .		1
104	Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future. Journal of Oncology, 2013, 2013, 1-12.	0.6	52
105	Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer. Journal of Oncology, 2013, 2013, 1-8.	0.6	15
106	Neoadjuvant Chemotherapy: Role in Breast Cancer. , 0, , .		1
107	Heterogeneity of Tumor Vasculature and Antiangiogenic Intervention: Insights from MR Angiography and DCE-MRI. PLoS ONE, 2014, 9, e86583.	1.1	21
108	The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFR β , Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer. PLoS ONE, 2014, 9, e102176.	1.1	49
109	Both Carboplatin and Bevacizumab Improve Pathological Complete Remission Rate in Neoadjuvant Treatment of Triple Negative Breast Cancer: A Meta-Analysis. PLoS ONE, 2014, 9, e108405.	1.1	29
110	Chemotherapy in Breast Cancer. The Ewha Medical Journal, 2014, 37, 75.	0.1	2
111	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget, 2014, 5, 4603-4650.	0.8	231
114	Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer. International Journal of Molecular Sciences, 2014, 15, 23024-23041.	1.8	54
115	Predictive Factors for Response to Neoadjuvant Therapy in Breast Cancer. Oncology Research and Treatment, 2014, 37, 5-5.	0.8	19
118	Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. Lancet Oncology, The, 2014, 15, 1493-1502.	5.1	109
119	Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis. International Journal of Cancer, 2014, 135, 1319-1329.	2.3	21
120	Bevacizumab Increases the Risk of Severe Congestive Heart Failure in Cancer Patients: An Up-to-Date Meta-Analysis with a Focus on Different Subgroups. Clinical Drug Investigation, 2014, 34, 681-690.	1.1	35
121	Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Molecular Medicine, 2014, 6, 1561-1576.	3.3	36
122	Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44â€“GeparQuinto). Annals of Oncology, 2014, 25, 2363-2372.	0.6	113
123	Differential Therapeutic Effects of Antiâ€“VEGF-A Antibody in Different Tumor Models: Implications for Choosing Appropriate Tumor Models for Drug Testing. Molecular Cancer Therapeutics, 2014, 13, 202-213.	1.9	14

#	ARTICLE	IF	CITATIONS
124	The life, death, and attempted rebirth of bevacizumab in breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 433-444.	0.5	5
125	Clinical Evaluation of Platinum Agents for the Treatment of Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 289-295.	0.5	1
126	Taxanes in combination with biologic agents for ovarian and breast cancers. <i>Anti-Cancer Drugs</i> , 2014, 25, 536-554.	0.7	2
127	New agents in locally advanced breast cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2014, 8, 64-69.	0.5	1
128	Breast cancer in young women: special considerations in multidisciplinary care. <i>Journal of Multidisciplinary Healthcare</i> , 2014, 7, 419.	1.1	36
129	Defining success in neoadjuvant breast cancer trials. <i>Lancet, The</i> , 2014, 384, 115-116.	6.3	20
130	Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. <i>Lancet Oncology, The</i> , 2014, 15, e42-e50.	5.1	427
131	Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. <i>Angiogenesis</i> , 2014, 17, 471-494.	3.7	626
132	Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 153-162.	1.1	92
134	Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen. <i>British Journal of Cancer</i> , 2014, 110, 1413-1419.	2.9	24
135	Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 228-234.	1.1	29
136	Inhibitors of Tumor Angiogenesis. , 2014, , 275-317.		1
137	Surgical treatment of primary breast cancer in the neoadjuvant setting. <i>British Journal of Surgery</i> , 2014, 101, 912-924.	0.1	59
138	Hypoxia-regulated gene network in drug resistance and cancer progression. <i>Experimental Biology and Medicine</i> , 2014, 239, 779-792.	1.1	45
139	Cardiotoxicity of systemic agents used in breast cancer. <i>Breast</i> , 2014, 23, 317-328.	0.9	49
140	When and How Do I Use Neoadjuvant Chemotherapy for Breast Cancer?. <i>Current Treatment Options in Oncology</i> , 2014, 15, 86-98.	1.3	47
141	Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2A–2 factorial randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 201-212.	5.1	106
142	Bevacizumab: A Review of Its Use in Advanced Cancer. <i>Drugs</i> , 2014, 74, 1891-1925.	4.9	142

#	ARTICLE	IF	CITATIONS
143	ASCO 2014: highlights in breast cancer. Memo - Magazine of European Medical Oncology, 2014, 7, 242-245.	0.3	0
144	Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. Journal of Pathology, 2014, 232, 142-150.	2.1	354
145	Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2014, 27, 161-170.	1.1	6
146	Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer, 2014, 111, 2051-2057.	2.9	26
147	Invasive lobular breast cancer and its variants: How special are they for systemic therapy decisions?. Critical Reviews in Oncology/Hematology, 2014, 92, 235-257.	2.0	65
148	Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials. Japanese Journal of Clinical Oncology, 2014, 44, 197-207.	0.6	55
150	Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study). British Journal of Cancer, 2014, 111, 1060-1064.	2.9	26
151	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Research and Treatment, 2014, 147, 61-68.	1.1	108
152	Current and future role of neoadjuvant therapy for breast cancer. Breast, 2014, 23, 526-537.	0.9	162
153	A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 229-238.	1.1	33
154	Revue de Presse de L'Espresso / Aerio Press Review. Oncologie, 2014, 16, 263-266.	0.2	0
155	Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44). Annals of Surgical Oncology, 2014, 21, 2517-2524.	0.7	23
157	Carboplatin for early triple-negative breast cancer?. Lancet Oncology, The, 2014, 15, 676-678.	5.1	3
158	A systematic review of bevacizumab efficacy in breast cancer. Cancer Treatment Reviews, 2014, 40, 960-973.	3.4	59
159	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology, The, 2014, 15, 747-756.	5.1	810
160	Triple-Negative Breast Cancer: One Or More Entities?. Forum of Clinical Oncology, 2014, 5, 20-31.	0.1	1
161	Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*. Breast Care, 2014, 9, 169-174.	0.8	9
162	Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years?. Breast Care, 2014, 9, 161-167.	0.8	5

#	ARTICLE	IF	CITATIONS
163	Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer. <i>Case Reports in Oncology</i> , 2014, 7, 252-259.	0.3	3
164	Two Cases of Mastectomy after Paclitaxel + Bevacizumab Therapy for Locally Advanced Breast Cancer. <i>Case Reports in Oncology</i> , 2014, 7, 323-329.	0.3	1
165	Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer. <i>Oncology Reports</i> , 2014, 32, 523-529.	1.2	39
166	Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean?. <i>BMC Medicine</i> , 2015, 13, 234.	2.3	39
167	Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. <i>International Journal of Cancer</i> , 2015, 137, 2981-2988.	2.3	31
168	Triple-negative breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, Publish Ahead of Print, 59-69.	0.9	71
169	The recent progress of neoadjuvant chemotherapy in triple negative breast cancer: A short review. <i>Journal of Solid Tumors</i> , 2015, 5, .	0.1	0
170	The role of taxanes in triple-negative breast cancer: literature review. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4303.	2.0	101
171	Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2015, 10, e0136324.	1.1	25
172	Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0133133.	1.1	7
173	Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy. <i>PLoS ONE</i> , 2015, 10, e0142190.	1.1	103
174	Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials. <i>PLoS ONE</i> , 2015, 10, e0145442.	1.1	23
175	Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. <i>Oncotarget</i> , 2015, 6, 42396-42410.	0.8	51
176	Triple negative breast cancer: looking for the missing link between biology and treatments. <i>Oncotarget</i> , 2015, 6, 26560-26574.	0.8	133
177	Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 88-104.	2.0	72
178	The fate of chemoresistance in triple negative breast cancer (TNBC). <i>BBA Clinical</i> , 2015, 3, 257-275.	4.1	293
179	Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14325-14330.	3.3	206
180	Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy. <i>Breast</i> , 2015, 24, S84-S87.	0.9	4

#	ARTICLE	IF	CITATIONS
181	Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data. <i>Clinical Cancer Research</i> , 2015, 21, 1298-1304.	3.2	56
182	Management of locally advanced breast cancer—perspectives and future directions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 147-162.	12.5	113
183	Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 141-148.	0.8	113
184	Genetic targeting of sprouting angiogenesis using Apln-CreER. <i>Nature Communications</i> , 2015, 6, 6020.	5.8	111
185	Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 251-265.	1.3	8
186	Targeting the Tumor Stroma in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 71-79.	0.5	0
187	Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 1118-1127.	0.7	77
188	Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 127-139.	1.1	92
189	Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 163-169.	1.1	16
190	Targeted Therapies in Triple-Negative Breast Cancer. <i>Breast Care</i> , 2015, 10, 159-166.	0.8	60
191	Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 377-387.	1.1	85
193	Bevacizumab: the phoenix of breast oncology?. <i>Lancet Oncology</i> , The, 2015, 16, 600-601.	5.1	8
194	Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 323-336.	2.0	24
195	Odds ratio vs risk ratio in randomized controlled trials. <i>Postgraduate Medicine</i> , 2015, 127, 359-367.	0.9	21
196	Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 557-567.	1.1	16
197	Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 5488-5498.	3.2	24
198	Soy and Breast Cancer: Focus on Angiogenesis. <i>International Journal of Molecular Sciences</i> , 2015, 16, 11728-11749.	1.8	149
199	Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. <i>Breast</i> , 2015, 24, 263-271.	0.9	13

#	ARTICLE	IF	CITATIONS
200	Future Translational Applications From the Contemporary Genomics Era. <i>Circulation</i> , 2015, 131, 1715-1736.	1.6	38
201	Therapies for triple negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 983-998.	0.9	85
202	Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 517-524.	0.8	2
203	The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials. <i>Tumor Biology</i> , 2015, 36, 1933-1941.	0.8	15
204	VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 481-489.	1.1	32
205	Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 577-587.	1.1	19
206	Osteopontin Regulates VEGFA and ICAM-1 mRNA Expression in Breast Carcinoma. <i>American Journal of Clinical Pathology</i> , 2015, 143, 812-822.	0.4	14
207	Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTEMIS): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 656-666.	5.1	114
208	New treatment strategies for patients with triple-negative breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 77-84.	0.9	22
209	Combined Neoadjuvant Chemotherapy With Bevacizumab Improves Pathologic Complete Response in Patients With Hormone Receptor Negative Operable or Locally Advanced Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 74-79.	0.6	16
210	Landscape of Neoadjuvant Therapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1408-1415.	0.7	47
211	Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. <i>Cancer Biology and Therapy</i> , 2015, 16, 790-798.	1.5	11
212	Comprehensive Review on the Surrogate Endpoints of Efficacy Proposed or Hypothesized in the Scientific Community Today. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 29-31.	0.9	14
213	Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1037-1048.	5.1	138
214	How high a bar to change neoadjuvant therapy for triple-negative breast cancer?. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 293-296.	0.6	0
215	Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer. <i>Future Oncology</i> , 2015, 11, 2563-2574.	1.1	1
216	The Efficacy and Safety of Preoperative Chemotherapy With Triweekly Abraxane and Cyclophosphamide Followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Therapy for Resectable Breast Cancer: A Multicenter Clinical Trial. <i>Clinical Breast Cancer</i> , 2015, 15, 110-116.	1.1	28
217	Neoadjuvant Therapy for Breast Cancer. <i>Annual Review of Medicine</i> , 2015, 66, 31-48.	5.0	55

#	ARTICLE	IF	CITATIONS
218	Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. Targeted Oncology, 2015, 10, 189-198.	1.7	33
219	Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology, 2015, 33, 13-21.	0.8	782
220	Do signal transduction cascades influence survival in triple-negative breast cancer? A preliminary study. OncoTargets and Therapy, 2016, 9, 3163.	1.0	0
221	Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis. PLoS ONE, 2016, 11, e0160148.	1.1	12
222	Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment. Cell Proliferation, 2016, 49, 409-420.	2.4	30
223	SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Research and Treatment, 2016, 158, 485-495.	1.1	75
224	High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 248-254.	0.6	11
225	The Impact of Neoadjuvant Treatment on Surgical Options and Outcomes. Annals of Surgical Oncology, 2016, 23, 3093-3099.	0.7	14
226	Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Supportive Care in Cancer, 2016, 24, 4057-4074.	1.0	21
227	Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer. Scientific Reports, 2016, 6, 36694.	1.6	15
228	Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients. Journal of NeuroVirology, 2016, 22, 736-746.	1.0	2
229	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). Journal of Clinical Oncology, 2016, 34, 2602-2609.	0.8	101
230	New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting. Cancer Medicine, 2016, 5, 2232-2239.	1.3	7
231	Effect of Body Mass Index and Actual Weight-Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer. Clinical Breast Cancer, 2016, 16, 480-486.	1.1	12
232	Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. EBioMedicine, 2016, 10, 109-116.	2.7	27
234	A Vesicle Supra-Assembly Approach to Synthesize Amine-Functionalized Hollow Dendritic Mesoporous Silica Nanospheres for Protein Delivery. Small, 2016, 12, 5169-5177.	5.2	72
235	Inflammation and Metastasis. , 2016, , .		4
236	Cancer in General. , 2016, , 165-192.		0

#	ARTICLE	IF	CITATIONS
237	Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy. <i>Expert Reviews in Molecular Medicine</i> , 2016, 18, e18.	1.6	36
238	A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer. <i>Future Oncology</i> , 2016, 12, 2589-2602.	1.1	6
239	Polydopamine-Functionalized Graphene Oxide Loaded with Gold Nanostars and Doxorubicin for Combined Photothermal and Chemotherapy of Metastatic Breast Cancer. <i>Advanced Healthcare Materials</i> , 2016, 5, 2227-2236.	3.9	54
241	Targeted adjuvant therapy in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1263-1275.	1.1	11
242	Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer. <i>Translational Oncology</i> , 2016, 9, 453-457.	1.7	113
243	Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy. <i>Scientific Reports</i> , 2016, 6, 30934.	1.6	29
244	Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S33163.	0.6	62
245	Brief-exposure to preoperative bevacizumab reveals a TGF β signature predictive of response in HER2-negative breast cancers. <i>International Journal of Cancer</i> , 2016, 138, 747-757.	2.3	16
246	Targeted drugs and Psycho-oncological intervention for breast cancer patients. <i>Journal of Negative Results in BioMedicine</i> , 2016, 15, 6.	1.4	6
247	Induction Chemotherapy for Breast Cancer. , 2016, , 131-156.		0
248	The therapeutic potential of mTOR inhibitors in breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1189-1212.	1.1	93
249	Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2016, 53, 65-74.	1.3	46
251	Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 39-50.	1.5	11
252	Patterns of prescribing radiotherapy and bevacizumab in nationwide practice – analysis of 101 designated cancer care hospitals in Japan. <i>Journal of Radiation Research</i> , 2016, 57, 157-163.	0.8	3
253	Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015. <i>Seminars in Radiation Oncology</i> , 2016, 26, 59-70.	1.0	11
254	Targeted Therapy of HER2-Negative Breast Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 118-121.	0.8	3
255	Targeting metastasis. <i>Nature Reviews Cancer</i> , 2016, 16, 201-218.	12.8	1,111
256	Translating neoadjuvant therapy into survival benefits: one size does not fit all. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 566-579.	12.5	38

#	ARTICLE	IF	CITATIONS
257	Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 600-611.	5.1	43
259	Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival. <i>Journal of Chemotherapy</i> , 2016, 28, 210-217.	0.7	15
260	Clinical and Molecular Methods in Drug Development: Neoadjuvant Systemic Therapy in Breast Cancer as a Model. <i>Methods in Molecular Biology</i> , 2016, 1395, 251-280.	0.4	0
261	Cancer of the Breast: An Overview. , 2016, , 147-209.		0
262	Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. <i>Clinical Cancer Research</i> , 2016, 22, 560-566.	3.2	79
263	Fatigue During and After Breast Cancer Therapyâ€”A Prospective Study. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 551-560.	0.6	44
264	Angiopoietin pathway gene expression associated with poor breast cancer survival. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 191-198.	1.1	51
266	Clinical results of randomized trials and â€œreal-worldâ€™ data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 497-506.	1.4	4
267	Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. <i>Oncologist</i> , 2017, 22, 245-254.	1.9	21
268	The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4662-4670.	3.2	31
269	Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. <i>Annals of Oncology</i> , 2017, 28, 1817-1824.	0.6	36
270	Triple-negative breast cancer: New therapeutic options via signalling transduction cascades. <i>Oncology Reports</i> , 2017, 37, 3055-3060.	1.2	10
271	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017, 77, 1313-1336.	4.9	39
272	The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 593-606.	1.1	3
273	Is complete response the answer?. <i>Annals of Oncology</i> , 2017, 28, 1681-1683.	0.6	6
274	Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma. <i>Lancet Oncology</i> , The, 2017, 18, e241-e242.	5.1	2
275	Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. <i>European Urology</i> , 2017, 72, 354-365.	0.9	195
276	Sorafenib for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 621-630.	0.9	29

#	ARTICLE	IF	CITATIONS
277	Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. <i>Lancet, The</i> , 2017, 389, 2430-2442.	6.3	640
278	Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. <i>Annals of Oncology</i> , 2017, 28, 754-760.	0.6	76
279	Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 53, 120-127.	3.4	178
280	Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. <i>Cancer Treatment Reviews</i> , 2017, 53, 98-110.	3.4	101
281	Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 210, 144-156.	0.5	29
282	Expression analysis of E-cad and vascular endothelial growth factor in triple-negative breast cancer patients of different ethnic groups in western China. <i>Medicine (United States)</i> , 2017, 96, e8155.	0.4	2
283	Câncer de mama inflamatorio. <i>EMC - Ginecologãa-Obstetricia</i> , 2017, 53, 1-9.	0.0	0
284	A case report of locally advanced triple negative breast cancer showing pathological complete response to weekly paclitaxel with bevacizumab treatment following disease progression during anthracycline-based neoadjuvant chemotherapy. <i>International Journal of Surgery Case Reports</i> , 2017, 39, 293-296.	0.2	0
285	Clinical pharmacology of anti-angiogenic drugs in oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 75-93.	2.0	13
286	Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data. <i>Current Oncology Reports</i> , 2017, 19, 56.	1.8	16
287	Surgical Outcomes for Mastectomy Patients Receiving Neoadjuvant Chemotherapy. <i>Annals of Surgery</i> , 2017, 265, 448-456.	2.1	22
288	Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. <i>Cancer Treatment Reviews</i> , 2017, 59, 123-131.	3.4	49
289	Effect of antitumor treatments on triple-negative breast cancer patients. <i>Medicine (United States)</i> , 2017, 96, e8389.	0.4	8
290	Primary Systemic Therapies: Guidelines. , 2017, , 541-548.		0
291	Revisiting the Role of Bevacizumab in the Treatment of Breast Cancer. <i>Seminars in Oncology</i> , 2017, 44, 273-285.	0.8	18
292	Breast cancer milestones 2007â€“2016. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 27-32.	0.3	0
293	Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. <i>Breast</i> , 2017, 34, S99-S103.	0.9	42
294	Influence of interstitial fluid dynamics on growth and therapy of angiogenic tumor. Analysis by mathematical model. <i>Biophysics (Russian Federation)</i> , 2017, 62, 129-137.	0.2	0

#	ARTICLE	IF	CITATIONS
295	No pain, no gain What we can learn from a trial reporting negative results. <i>Annals of Oncology</i> , 2017, 28, 678-680.	0.6	2
296	Disrupting Tumor Angiogenesis and "the Hunger Games" for Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 171-195.	0.8	11
297	Chest Wall Disease: The Clinical Continuum between Inflammatory and Lymphangitic Breast Cancer. <i>Breast</i> , 2017, 36, S25.	0.9	0
298	Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 101.	1.8	65
299	Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B. <i>Nature Communications</i> , 2017, 8, 269.	5.8	67
300	Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel. <i>Cancer Letters</i> , 2018, 419, 233-244.	3.2	13
301	Rethinking neoadjuvant chemotherapy for breast cancer. <i>BMJ: British Medical Journal</i> , 2018, 360, j5913.	2.4	73
302	Clinical relevance and concordance of HER2 status in local and central testing"an analysis of 1581 HER2-positive breast carcinomas over 12 years. <i>Modern Pathology</i> , 2018, 31, 607-615.	2.9	25
303	Therapeutic Strategies for Breast Cancer. , 2018, , 315-330.e7.		5
304	Locally Advanced Breast Cancer. , 2018, , 819-831.e6.		3
305	Neoadjuvant Chemotherapy and Radiotherapy. , 2018, , 839-857.e7.		0
306	Locally Advanced Breast Cancer. , 2018, , 567-578.		0
307	On baseball and breast cancer. <i>American Journal of Surgery</i> , 2018, 215, 353-356.	0.9	0
308	Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 59-71.	1.1	32
309	Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. <i>International Journal of Cancer</i> , 2018, 142, 618-628.	2.3	27
310	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. <i>Lancet Oncology</i> , The, 2018, 19, 40-50.	5.1	1,327
311	Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: Diagnosis and therapeutic implications. <i>Journal of Cellular Physiology</i> , 2018, 233, 3729-3744.	2.0	73
312	Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. <i>Oncotarget</i> , 2018, 9, 15168-15179.	0.8	29

#	ARTICLE	IF	CITATIONS
313	BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2281-2287.	0.8	86
314	Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). <i>Journal of Clinical Oncology</i> , 2018, 36, 2621-2629.	0.8	52
315	Oestrogen Inhibits VEGF Expression And Angiogenesis In Triple-Negative Breast Cancer By Activating GPER-1. <i>Journal of Cancer</i> , 2018, 9, 3802-3811.	1.2	18
316	Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 9049-9059.	1.0	4
317	Distribution and prognostic value of tumor-infiltrating T cells in breast cancer. <i>Molecular Medicine Reports</i> , 2018, 18, 4247-4258.	1.1	18
318	Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5059-5074.	1.0	23
319	Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 147-152.	0.7	4
320	The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 747-758.	1.1	12
321	Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. <i>International Journal of Cancer</i> , 2018, 143, 2905-2918.	2.3	28
322	Genetic Markers in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e841-e850.	1.1	148
323	Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol. <i>Systematic Reviews</i> , 2018, 7, 89.	2.5	25
324	Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study. <i>Clinical Drug Investigation</i> , 2018, 38, 639-648.	1.1	20
325	Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. <i>Cancer Management and Research</i> , 2018, Volume 10, 91-103.	0.9	53
326	Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab. <i>Oncolmmunology</i> , 2018, 7, e1457598.	2.1	18
327	The Effect of Perioperative Bevacizumab on Disease-Free and Overall Survival in Locally Advanced HER-2 Negative Breast Cancer: A Meta-Analysis. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341879225.	0.6	7
328	miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer. <i>Molecular Oncology</i> , 2019, 13, 2278-2296.	2.1	30
329	Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. <i>Annals of Surgical Oncology</i> , 2019, 26, 3892-3901.	0.7	29
330	Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS+EG score. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 437-446.	1.1	5

#	ARTICLE	IF	CITATIONS
331	Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents. <i>Scientific Reports</i> , 2019, 9, 9204.	1.6	3
332	Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1608.	1.0	2
333	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. <i>International Journal of Cancer</i> , 2019, 145, 857-868.	2.3	12
334	Effectiveness of Added Targeted Therapies to Neoadjuvant Chemotherapy for Breast Cancer: A Systematic Review and Meta-analysis. <i>Clinical Breast Cancer</i> , 2019, 19, e690-e700.	1.1	8
335	A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling. <i>Cell Chemical Biology</i> , 2019, 26, 1143-1158.e6.	2.5	53
336	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 612.	1.0	5
337	Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials. <i>Molecular and Clinical Oncology</i> , 2019, 10, 357-365.	0.4	14
338	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. <i>Oncologist</i> , 2019, 24, 603-611.	1.9	43
339	Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. <i>Gynecologic Oncology</i> , 2019, 152, 235-242.	0.6	10
340	Functional Proteomics of Breast Cancer Metabolism Identifies GLUL as Responder during Hypoxic Adaptation. <i>Journal of Proteome Research</i> , 2019, 18, 1352-1362.	1.8	9
341	Potential of Liquid Biopsies for Breast Cancer Screening, Diagnosis, and Response to Treatment. <i>Oncology</i> , 2019, 96, 115-124.	0.9	11
342	A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer. <i>Cancer Medicine</i> , 2019, 8, 383-399.	1.3	14
343	Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. <i>British Journal of Cancer</i> , 2019, 120, 196-206.	2.9	27
344	Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers. <i>International Journal of Cancer</i> , 2020, 146, 223-235.	2.3	13
345	Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 35-45.	3.2	22
346	Comparative Toxicities of Neoadjuvant Chemotherapy With or Without Bevacizumab in HER2-Negative Breast Cancer Patients: A Meta-analysis. <i>Annals of Pharmacotherapy</i> , 2020, 54, 517-525.	0.9	2
347	Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study. <i>EClinicalMedicine</i> , 2020, 28, 100566.	3.2	6
348	Tumor necrosis factor β inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer. <i>Cell Death and Disease</i> , 2020, 11, 993.	2.7	31

#	ARTICLE	IF	CITATIONS
349	Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis. <i>Journal of International Medical Research</i> , 2020, 48, 030006052096434.	0.4	14
350	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. <i>Cancers</i> , 2020, 12, 2392.	1.7	171
351	Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 2515-2525.	2.3	13
352	Regimens of neo-adjuvant chemotherapy in the treatment of breast cancer: A systematic review & network meta-analysis with PRISMA-NMA compliance. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103015.	2.0	7
353	A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. <i>Clinical Cancer Research</i> , 2020, 26, 1896-1904.	3.2	9
354	Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis. <i>BMC Cancer</i> , 2020, 20, 180.	1.1	6
355	The history, present situation, and future directions of neoadjuvant chemotherapy for HER2-negative breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 29-29.	0.4	9
356	Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database. <i>BMC Cancer</i> , 2020, 20, 136.	1.1	8
357	TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 22.	2.2	10
358	Remodeling of Metastatic Vasculature Reduces Lung Colonization and Sensitizes Overt Metastases to Immunotherapy. <i>Cell Reports</i> , 2020, 30, 714-724.e5.	2.9	51
359	Angiocrine endothelium: from physiology to cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 52.	1.8	53
360	The Landscape of Targeted Therapies in TNBC. <i>Cancers</i> , 2020, 12, 916.	1.7	232
361	Molecular subtypes and precision treatment of triple-negative breast cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 499-499.	0.7	64
362	Screening of Clinical Factors Related to Prognosis of Breast Cancer Based on the Cox Proportional Risk Model. <i>Journal of Computational Biology</i> , 2021, 28, 89-98.	0.8	2
363	Hypoxia and perfusion in breast cancer: simultaneous assessment using PET/MR imaging. <i>European Radiology</i> , 2021, 31, 333-344.	2.3	32
364	Triple-negative breast cancer: promising prognostic biomarkers currently in development. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 135-148.	1.1	80
365	Triple-negative breast cancer: new treatment strategies in the era of precision medicine. <i>Science China Life Sciences</i> , 2021, 64, 372-388.	2.3	26
366	Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers. <i>JCO Precision Oncology</i> , 2021, 5, 286-306.	1.5	5

#	ARTICLE	IF	CITATIONS
367	Bevacizumab Plays a double-edged role in Neoadjuvant Therapy for Non-metastatic Breast Cancer: A Systemic Review and Meta-Analysis. <i>Journal of Cancer</i> , 2021, 12, 2643-2653.	1.2	1
368	Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. <i>Cancers</i> , 2021, 13, 140.	1.7	4
369	Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110284.	1.4	12
370	Phosphatidylserine-exposing tumor-derived microparticles exacerbate coagulation and cancer cell transendothelial migration in triple-negative breast cancer. <i>Theranostics</i> , 2021, 11, 6445-6460.	4.6	12
371	Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 457-467.	3.3	13
372	Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer. <i>Scientific Reports</i> , 2021, 11, 3388.	1.6	14
373	Gene Expression-Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. <i>Clinical Cancer Research</i> , 2021, 27, 2148-2158.	3.2	12
374	Modulation of the Vascular-Immune Environment in Metastatic Cancer. <i>Cancers</i> , 2021, 13, 810.	1.7	12
375	Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia – A case-based review of clinical management. <i>Thrombosis Research</i> , 2021, 199, 38-42.	0.8	6
376	Sample size re-estimation for covariate-adaptive randomized clinical trials. <i>Statistics in Medicine</i> , 2021, 40, 2839-2858.	0.8	1
377	Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2021, 145, 44-52.	1.3	5
378	Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103280.	2.0	22
379	Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis. <i>Npj Breast Cancer</i> , 2021, 7, 42.	2.3	32
381	Precision medicine for the treatment of triple negative breast cancer: opportunities and challenges. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 259-270.	0.4	1
382	Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. <i>European Journal of Cancer</i> , 2021, 148, 51-57.	1.3	16
383	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 159-170.	1.3	41
384	Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials. <i>Journal of Chemotherapy</i> , 2022, 34, 221-234.	0.7	3
385	Utility of the CPS+ÂEG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2021, 153, 203-212.	1.3	8

#	ARTICLE	IF	CITATIONS
386	A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer. <i>Anti-Cancer Drugs</i> , 2022, 33, e52-e60.	0.7	7
387	Does bevacizumab carry a hope for metastatic triple-negative breast cancer in the era of immunotherapy?. <i>Anti-Cancer Drugs</i> , 2022, 33, e604-e609.	0.7	3
388	Blood Vessels and Peripheral Nerves as Key Players in Cancer Progression and Therapy Resistance. <i>Cancers</i> , 2021, 13, 4471.	1.7	10
389	Effect of Adding Bevacizumab to Chemotherapy on Pathologic Response to Preoperative Systemic Therapy for Resectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2021, 20, 265-272.	1.0	7
390	Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102283.	3.4	13
391	The Value of Antiangiogenics in Breast Cancer Therapy. , 2017, , 1-13.		1
392	Questioning Our APHINITY for More. <i>New England Journal of Medicine</i> , 2017, 377, 186-187.	13.9	15
393	Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. <i>JCI Insight</i> , 2016, 1, e87754.	2.3	11
394	Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy. <i>JCI Insight</i> , 2016, 1, e90733.	2.3	19
395	RAS interaction with PI3K p110 α is required for tumor-induced angiogenesis. <i>Journal of Clinical Investigation</i> , 2014, 124, 3601-3611.	3.9	65
396	Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future. <i>Breast Cancer: Basic and Clinical Research</i> , 2020, 14, 117822342098037.	0.6	50
397	The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review. <i>PLoS ONE</i> , 2013, 8, e51780.	1.1	72
398	Phase III Trials of Standard Chemotherapy with or without Bevacizumab for Ovarian Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e81858.	1.1	36
399	Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes. <i>Critical Reviews in Oncogenesis</i> , 2016, 21, 333-351.	0.2	44
400	Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 35205-35221.	0.8	48
401	Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. <i>Oncotarget</i> , 2017, 8, 51492-51506.	0.8	38
402	Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. <i>Oncotarget</i> , 2014, 5, 6994-7012.	0.8	14
403	High expression of apoptosis protein (Api-5) in chemoresistant triple-negative breast cancers: an innovative target. <i>Oncotarget</i> , 2019, 10, 6577-6588.	0.8	9

#	ARTICLE	IF	CITATIONS
404	Triple Negative Breast Cancer: A Review of Clinicopathologic Characteristics And Treatment Options. Open Breast Cancer Journal, 2014, 6, 1-8.	0.2	1
405	STUDY OF ACUTE VIRAL MENINGOENCEPHALITIS IN CHILDREN IN SUB-HIMALAYAN TARAI REGION: CLINICO-EPIDEMIOLOGICAL, ETIOLOGICAL, AND IMAGING PROFILE. Indian Journal of Child Health, 2015, 02, 177-181.	0.2	6
406	Antiangiogenic mechanisms and factors in breast cancer treatment. Journal of Carcinogenesis, 2016, 15, 1.	2.5	39
407	Past, present and future of primary systemic treatment in breast cancer. World Journal of Obstetrics and Gynecology, 2013, 2, 21.	0.5	1
408	Taxane and Anthracycline Based Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer : Institutional Experience. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1989-1992.	0.5	21
409	Cancer in General. , 2021, , 171-198.		0
411	Systemische Induktionschemotherapie bei Brustkrebs. , 2013, , 127-138.		0
413	Preoperative Systemic Therapy. Updates in Surgery Series, 2014, , 269-282.	0.0	0
414	Neoadjuvant Chemotherapeutic and Targeted Therapies for Early-stage, High-risk Breast Cancer. European Oncology and Haematology, 2014, 10, 28.	0.0	0
418	Preoperative Therapy for Operable Breast Cancer. , 2016, , 251-263.		0
419	Angiogenesis Inhibition in Breast Cancer. , 2016, , 589-616.		0
420	Systemic Therapy. , 2016, , 335-390.		0
421	Systemic Therapy for Locally Advanced Breast Cancer. , 2016, , 271-283.		0
422	Chest Wall Disease: The Clinical Continuum Between Inflammatory and Lymphangitic Breast Cancer. , 2017, , 719-727.		0
423	Antiangiogenic Therapy Combined with Chemotherapy Including Platinum Agents as a Therapeutic Option for Triple Negative Breast Cancer. Chemotherapy, 2018, 07, .	0.0	0
424	Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight, 2018, 3, .	2.3	9
425	Breast Cancer: Risk Factors, Diagnosis and Management. Medical Laboratory Journal, 2018, 12, 1-9.	0.1	1
426	Preoperative Systemic Therapy for Operable Breast Cancer. , 2019, , 241-261.		0

#	ARTICLE	IF	CITATIONS
427	Targeting Cancer from a Structural Biology Perspective. , 2019, , 295-320.		0
428	Systemic Therapy for Locally Advanced Breast Cancer. , 2019, , 247-257.		0
429	Preoperative Therapy for Operable Breast Cancer. , 2019, , 223-238.		0
430	The Value of Anti-angiogenics in Breast Cancer Therapy. , 2019, , 515-527.		0
431	Angiogenesis Inhibition in Breast Cancer. , 2019, , 507-528.		0
432	The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study. Translational Cancer Research, 2019, 8, S94-S96.	0.4	1
433	A new paradox for pCR in BRCA mutation carriers. Translational Cancer Research, 2019, 8, S99-S102.	0.4	0
434	Comparison of the incidence of perioperative cardiovascular risk events among patients with and without a history of neoadjuvant chemotherapy. Minerva Anestesiologica, 2019, 85, 822-829.	0.6	4
436	Risk of Hypertension Associated with Antivasular Endothelial Growth Factor Monoclonal Antibodies: A Meta-Analysis From 51088 Patients with Cancer. Iranian Red Crescent Medical Journal, 2020, 22, .	0.5	2
438	Prediction of neoadjuvant chemotherapy response in breast cancer. EXCLI Journal, 2021, 20, 625-627.	0.5	0
439	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. European Journal of Cancer, 2022, 160, 100-111.	1.3	12
440	Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110595.	1.4	10
441	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 1323-1334.	0.8	62
442	Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer. Cancer Research, 2022, 82, 1396-1408.	0.4	13
443	Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. Frontiers in Pharmacology, 2022, 13, 838133.	1.6	39
444	Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. European Journal of Cancer, 2022, 166, 185-201.	1.3	13
447	Effect of modified radical mastectomy combined with neo-adjuvant chemotherapy on postoperative recurrence rate, negative emotion, and life quality of patients with breast cancer.. American Journal of Translational Research (discontinued), 2022, 14, 460-467.	0.0	0
448	Triple-Negative Breast Cancer: the Current Aspects of Pathogenesis and Therapies. BioNanoScience, 2022, 12, 1404-1435.	1.5	2

#	ARTICLE	IF	CITATIONS
450	Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
451	Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211180.	1.4	4
452	Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis. <i>Hereditary Cancer in Clinical Practice</i> , 2022, 20, .	0.6	5
453	Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	0
454	Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer. <i>Cancers</i> , 2022, 14, 5456.	1.7	8
455	“Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research”™. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1291-1310.	1.9	2
456	Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2(+) breast cancer, multiple myeloma, and non-small-cell lung cancer. <i>Journal of the Egyptian National Cancer Institute</i> , 2022, 34, .	0.6	1
457	Herbal Medicine: Prejudice to Realm of Reality Against TNBC. , 2023, , 123-144.		0
458	Pre-Clinical and Clinical Evidence of Recent Therapeutic Trends and Spotting Possibility of Cure in Near Future. , 2023, , 73-98.		0
459	De-ESCALating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study. <i>Breast Cancer Research and Treatment</i> , 2023, 199, 81-89.	1.1	5
460	Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	2
462	Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	6
463	PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	1
464	Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	1